Clinical development is not simply a sequence of studies. It is a structured programme used to generate evidence about whether a medical product can be used safely and effectively. The process links laboratory discovery, nonclinical research, human studies, regulatory review, and post-marketing evidence generation.
What clinical development includes
Clinical development commonly refers to studies conducted in human participants, but it operates within a broader product-development lifecycle. The process begins with discovery and candidate development, moves through preclinical work, then into clinical research, regulatory review, and post-market safety monitoring.
1. Discovery and candidate development
Discovery begins with a scientific hypothesis about a disease, a biological pathway, a target, or an existing treatment. Researchers may screen compounds, develop biological products, explore new delivery technologies, or investigate new uses for known substances. Promising candidates are characterised to understand mechanism of action, clinical potential, dose range, toxicity, and feasibility.
2. Preclinical development
Preclinical work investigates whether a candidate has sufficient biological activity and an acceptable safety basis to justify initial human exposure. These studies may involve laboratory experiments, animal studies, pharmacology, pharmacokinetics, toxicology, and formulation work.
3. Designing the development plan
Before clinical trials begin, sponsors should prepare an integrated development plan that connects the target product profile with the studies needed to support the indication, population, dose, route, duration, safety monitoring, and marketing strategy. The plan should address feasibility, protocol quality, data reliability, and the resources needed to execute the programme.
Critical planning questions
- What clinical question must the study answer?
- Which population can answer that question ethically and reliably?
- Which endpoint is clinically meaningful and measurable?
- Can suitable sites recruit and retain the required participants?
- Which safety risks require enhanced monitoring?
4. Clinical trial phases
Clinical trials are commonly described as Phase I, II, III, and IV, although programmes increasingly use adaptive, seamless, platform, and pragmatic designs. Each phase has a different purpose: early studies examine safety and dose, later studies evaluate efficacy and benefit-risk, and post-approval studies address longer-term performance and broader use.
5. Protocol, site, and operational planning
The protocol defines the study objective, design, population, intervention, endpoints, statistical approach, and safety procedures. Unnecessary complexity increases site burden, protocol deviations, costs, and the risk of unusable data. Feasibility should test assumptions about investigator experience, patient availability, laboratories, pharmacies, ethics timelines, data systems, and staffing.
6. Ethics, Good Clinical Practice, and participant protection
Clinical trials must be scientifically valid and ethically acceptable. Participants should receive clear information about the study, foreseeable risks, potential benefits, alternatives, confidentiality, compensation, and the voluntary nature of participation before providing informed consent. Good Clinical Practice establishes responsibilities for sponsors, investigators, ethics committees, and other parties.
7. Trial conduct, data, and safety oversight
During trial conduct, investigators enrol eligible participants, perform protocol-defined procedures, document outcomes, manage investigational products, and report safety information. Sponsors maintain oversight even when activities are delegated to a contract research organisation or other vendor. Monitoring should focus on risks that could materially affect participant safety or the reliability of results.
Key takeaways
- Clinical development must be driven by clear scientific and business questions.
- Feasibility, ethics, quality, and operational planning should be addressed early.
- Regulatory alignment and participant protection are essential from the start.
8. Regulatory review and market authorisation
After the required studies are completed, the sponsor compiles quality, nonclinical, clinical, statistical, and pharmacovigilance evidence into a marketing-authorisation application. Regulators assess whether the evidence supports the proposed indication, population, dose, product information, manufacturing controls, and risk-management measures. Approval does not mean that every uncertainty has been resolved; it means the regulator has determined that the product’s benefits outweigh its known and reasonably characterised risks for the authorised conditions of use.
Clinical development in Nigeria
In Nigeria, no clinical trial may commence without written authorisation from NAFDAC. Applications are submitted through the electronic Clinical Trial Application Platform, and ethics and NAFDAC review may proceed in parallel. Strong planning is essential to avoid delays, preserve data quality, and support timely decision-making.
MedNova supports clinical development planning, protocol development, feasibility, site identification, regulatory and ethics submissions, monitoring, safety oversight, data management, and study reporting. We also help teams connect these activities with regulatory strategy, pharmacovigilance, and regulatory affairs guidance.
Need support with your clinical development programme?
MedNova Lifesciences helps sponsors and investigators plan studies, strengthen feasibility, manage regulatory and ethics pathways, and build reliable operational readiness in Nigeria and across the region.
Request a consultation